Cargando…

Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat

We report the case of a 40-year-old patient with systemic sclerosis (SSc) and systemic lupus erythematosus (SLE) overlap syndrome with pulmonary arterial hypertension (overlap-PAH) that was successfully treated with a combination of immunosuppressive therapy and the soluble guanylate cyclase stimula...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuzuya, Kentaro, Tsuji, Soichiro, Matsushita, Masato, Ohshima, Shiro, Saeki, Yukihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538401/
https://www.ncbi.nlm.nih.gov/pubmed/31183306
http://dx.doi.org/10.7759/cureus.4327
_version_ 1783422175671222272
author Kuzuya, Kentaro
Tsuji, Soichiro
Matsushita, Masato
Ohshima, Shiro
Saeki, Yukihiko
author_facet Kuzuya, Kentaro
Tsuji, Soichiro
Matsushita, Masato
Ohshima, Shiro
Saeki, Yukihiko
author_sort Kuzuya, Kentaro
collection PubMed
description We report the case of a 40-year-old patient with systemic sclerosis (SSc) and systemic lupus erythematosus (SLE) overlap syndrome with pulmonary arterial hypertension (overlap-PAH) that was successfully treated with a combination of immunosuppressive therapy and the soluble guanylate cyclase stimulator riociguat. She was diagnosed with mixed connective tissue disease (MCTD) two years prior to admission. She was admitted to our hospital with dyspnea on exertion and progressive skin sclerosis. She fulfilled both SLE and SSc classification criteria and was re-diagnosed with overlap syndrome. The tricuspid valve pressure gradient (TRPG) on echocardiography was 64 mmHg at admission. On right heart catheterization, mean pulmonary arterial pressure (mPAP) was 43 mmHg and pulmonary capillary wedge pressure was 15 mmHg. We diagnosed her with SSc-SLE overlap-PAH and started treatment with corticosteroids and intravenous cyclophosphamide. We also started treatment with riociguat because we speculated she had a component of SSc-PAH and that immunosuppressive therapy alone may be insufficient. We chose riociguat because of its favorable treatment effect on SSc-PAH. Two months after treatment, her TRPG improved to 33 mmHg and the skin sclerosis improved dramatically, suggesting the efficacy of multi-drug treatment and the importance of early intervention.
format Online
Article
Text
id pubmed-6538401
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-65384012019-06-10 Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat Kuzuya, Kentaro Tsuji, Soichiro Matsushita, Masato Ohshima, Shiro Saeki, Yukihiko Cureus Cardiology We report the case of a 40-year-old patient with systemic sclerosis (SSc) and systemic lupus erythematosus (SLE) overlap syndrome with pulmonary arterial hypertension (overlap-PAH) that was successfully treated with a combination of immunosuppressive therapy and the soluble guanylate cyclase stimulator riociguat. She was diagnosed with mixed connective tissue disease (MCTD) two years prior to admission. She was admitted to our hospital with dyspnea on exertion and progressive skin sclerosis. She fulfilled both SLE and SSc classification criteria and was re-diagnosed with overlap syndrome. The tricuspid valve pressure gradient (TRPG) on echocardiography was 64 mmHg at admission. On right heart catheterization, mean pulmonary arterial pressure (mPAP) was 43 mmHg and pulmonary capillary wedge pressure was 15 mmHg. We diagnosed her with SSc-SLE overlap-PAH and started treatment with corticosteroids and intravenous cyclophosphamide. We also started treatment with riociguat because we speculated she had a component of SSc-PAH and that immunosuppressive therapy alone may be insufficient. We chose riociguat because of its favorable treatment effect on SSc-PAH. Two months after treatment, her TRPG improved to 33 mmHg and the skin sclerosis improved dramatically, suggesting the efficacy of multi-drug treatment and the importance of early intervention. Cureus 2019-03-26 /pmc/articles/PMC6538401/ /pubmed/31183306 http://dx.doi.org/10.7759/cureus.4327 Text en Copyright © 2019, Kuzuya et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Kuzuya, Kentaro
Tsuji, Soichiro
Matsushita, Masato
Ohshima, Shiro
Saeki, Yukihiko
Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat
title Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat
title_full Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat
title_fullStr Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat
title_full_unstemmed Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat
title_short Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat
title_sort systemic sclerosis and systemic lupus erythematosus overlap syndrome with pulmonary arterial hypertension successfully treated with immunosuppressive therapy and riociguat
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538401/
https://www.ncbi.nlm.nih.gov/pubmed/31183306
http://dx.doi.org/10.7759/cureus.4327
work_keys_str_mv AT kuzuyakentaro systemicsclerosisandsystemiclupuserythematosusoverlapsyndromewithpulmonaryarterialhypertensionsuccessfullytreatedwithimmunosuppressivetherapyandriociguat
AT tsujisoichiro systemicsclerosisandsystemiclupuserythematosusoverlapsyndromewithpulmonaryarterialhypertensionsuccessfullytreatedwithimmunosuppressivetherapyandriociguat
AT matsushitamasato systemicsclerosisandsystemiclupuserythematosusoverlapsyndromewithpulmonaryarterialhypertensionsuccessfullytreatedwithimmunosuppressivetherapyandriociguat
AT ohshimashiro systemicsclerosisandsystemiclupuserythematosusoverlapsyndromewithpulmonaryarterialhypertensionsuccessfullytreatedwithimmunosuppressivetherapyandriociguat
AT saekiyukihiko systemicsclerosisandsystemiclupuserythematosusoverlapsyndromewithpulmonaryarterialhypertensionsuccessfullytreatedwithimmunosuppressivetherapyandriociguat